🇺🇸

US SEC Filing Intelligence

· daily

USA Insider Trading Pulse — July 20, 2026

The July 20, 2026 insider trading pulse reveals a market characterized by cautious insider selling at elevated levels, particularly within the biotech and tech sectors, while notable insider buying is concentrated in small-cap and distressed names, signaling potential value opportunities. A significant cluster of 10b5-1 plan sales from multiple C-suite executives at Sea Ltd, MapLight Therapeutics, and Nexxen International suggests pre-planned, tax-related, or liquidity-driven selling rather than outright bearish sentiment, though the volume warrants monitoring. Conversely, a strong bullish signal emerges from Flora Growth Corp., where the Executive Chairman deployed $3.48M in a massive open-market purchase, and from a director at abrdn Healthcare funds who made coordinated, equal-value purchases across four closed-end funds, indicating a targeted value play. The day is dominated by neutral, non-discretionary events such as equity awards and tax-withholding sales, which do not reflect management conviction. Key themes include a concentration of insider selling in biotech (Incyte, MoonLake, MapLight), a pattern of insider buying in deeply undervalued small-caps (Flora Growth, 17 Education, SOLAI), and a notable lack of forward-looking guidance or capital allocation changes in the filings, limiting catalyst visibility. The most actionable intelligence lies in the contrast between the high-conviction buying in select micro-caps and the systematic, 10b5-1-driven selling in growth and biotech names, suggesting a rotation from momentum to deep value.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 20, 2026

The July 20, 2026 M&A landscape is dominated by SPAC turbulence and precious metals consolidation. Two SPACs (Compass Digital, DT Cloud Star) face imminent dissolution or delisting due to failed business combinations and regulatory non-compliance, while Drugs Made In America navigates a complex three-party merger with massive shareholder redemptions. In precious metals, Gold Resource Corp's acquisition by Goldgroup Mining creates a combined entity with diversified Mexican and US assets, signaling sector consolidation. Aterian's asset sale and CVR issuance represents a distressed restructuring, while Aptorum Group's merger with DiamiR and reverse split aims for a Nasdaq fresh start. Mawson Infrastructure's JV acquisition of a Texas power site for AI/HPC use highlights the growing convergence of energy and digital infrastructure. Insider activity is sparse but notable, with Oxley Bridge's board resignation and Compass Digital's unanimous shareholder vote for wind-up indicating management alignment with dissolution. The period-over-period data reveals no revenue or margin trends as most filings are event-driven 8-Ks, but capital allocation patterns show a clear preference for cash preservation and trust account redemptions over growth investment.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 20, 2026

This pre-market digest covers 50 filings, with a heavy concentration of 13F-HR institutional holdings updates (12 filings) that provide a snapshot of Q2 2026 positioning but lack period-over-period comparisons. The most actionable themes center on corporate actions: Jersey Mike's Subs is moving forward with a high-profile IPO (expected price range $21-$25), while DRC Medicine's SPAC merger with Ribbon Acquisition Corp is progressing (DRC holders to own ~85.78% of the combined entity). In the energy and mining space, Gold Resource Corp is being acquired by Goldgroup Mining, with the combined entity trading under 'GORO'. Domino's Pizza reported a sharp deceleration in US same-store sales (0.1% vs 3.4% a year ago), signaling a potential consumer spending slowdown. Flex Ltd. announced a major strategic spin-off of its Cloud and Power Infrastructure segment, achieving its FY27 margin target a year early. Insider activity is limited, but a controlling stake disclosure in Margaree Acquisition Corp (75% by Mark N. Tompkins) and a significant stake increase by Korea's NPS in Shinhan Financial Group (to 9.19%) are notable. The most critical risks include a financial restatement at Adapti, Inc. and a going concern warning from Spectral Capital Corp. The overall tone is mixed, with several high-conviction corporate events offset by operational headwinds in consumer-facing sectors.

11 high priority 39 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 18, 2026

This digest covers 7 FDA approvals from July 13-14, 2026, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 7 'Other' approvals (all generic/biosimilar entries). The dominant theme is generic erosion across multiple therapeutic areas, with no single therapeutic area clustering. The highest-conviction signal is the NME approval of GEDATOLISIB (REVTORPYK) by CELCUITY INC., granted Priority Review, representing a rare bullish catalyst in an otherwise neutral period. Key risk: the absence of NME approvals outside of CELCUITY's single event signals a weak innovation cycle for small-cap biotech sponsors during this window.

7 total filings
· daily

NME Blockbuster Approvals — July 18, 2026

The July 18, 2026, FDA approval period contains a single approval event: the NME approval of GEDATOLISIB (REVTORPYK) by CELCUITY INC., granted Priority Review. While classified as a FALLBACK-type approval, this represents a positive signal for CELCUITY’s execution capability and strengthens sentiment around small-molecule innovation outside of standard drug classes. No biosimilar or label expansion approvals were recorded, limiting differential competitive reads. The highest-conviction signal is from CELCUITY’s first NME approval, though the lack of disclosure on peak sales, exclusivity, pricing power, and market position tempers the near-term commercial thesis. The key risk remains the absence of commercial benchmarks (pricing, exclusivity length, market position) which are essential for peak sales modeling and competitive positioning.

1 total filings
· daily

Big Pharma Approvals — July 18, 2026

On July 18, 2026, the FDA issued 3 label expansion approvals, all classified as 'FALLBACK' type with bullish signals of moderate strength and materiality (5/10 each). There were zero NMEs, biosimilars, or standard label expansions in this period, indicating a quiet day for high-impact regulatory catalysts. The two approvals for SELPERCATINIB (RETEVMO, Eli Lilly) for separate indications signal a deliberate strategy to maximize the RET inhibitor's lifecycle, while the single ENLICITIDE CHLORIDE (Merck Sharp & Dohme) label expansion adds incremental optionality to Merck's pipeline. All three are rated broadly bullish, but the lack of NME approvals or biosimilar entries means there is no transformative commercial signal or competitive disruption present. Key risks include potential IRA exposure for SELPERCATINIB as a small molecule, and the limited available commercial data (all NOT_DISCLOSED) prevents full valuation assessment.

3 total filings
· daily

Orphan Drug Approvals — July 18, 2026

During July 18, 2026, the FDA issued two label expansion approvals for SELPERCATINIB (RETEVMO) by ELI LILLY AND CO, classified as 'Other' with no NME, biosimilar, or standard label expansion mix. Both approvals carry a bullish signal with moderate strength and materiality, suggesting incremental commercial value for LILLY's RETEVMO franchise, though specific indication details and peak sales estimates are NOT_DISCLOSED. The lack of NME or biosimilar approvals in this period limits sector-level innovation signals, but the dual approval for the same drug on the same day may indicate a strategic push to broaden label utility. The highest-conviction signal is the label expansion for SELPERCATINIB, which could support LILLY's oncology portfolio, but absence of disclosed clinical or market detail tempers conviction. Key risks include any potential confirmatory trial requirements or competitive pressure from other RET inhibitors like LOXO-292 in the RET-altered tumor landscape.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — July 18, 2026

This digest covers a single $120.6M civilian infrastructure contract awarded to H-K CONTRACTORS by the Department of Transportation/FHWA for the Yellowstone River Bridge in Wyoming. With zero defense-related awards, the period is entirely civilian, dominated by traditional heavy construction under a firm-fixed-price structure. The highest-conviction signal is neutral: the contract provides steady revenue visibility through November 2026, but $22.6M in remaining obligations and fixed-price risk on a multi-year project warrant monitoring. Key risk: execution delays or cost overruns on the fixed-price bridge replacement could compress margins for H-K CONTRACTORS.

1 total filings
· daily

DHS Homeland Security Contracts — July 18, 2026

The single contract digest for July 18, 2026, covers a $73 million DHS Homeland Security award to THOR SOLUTIONS LLC, a Service-Disabled Veteran-Owned Small Business, for U.S. Coast Guard engineering support services. The contract is entirely civilian, with no defense-related exposure, and carries a neutral signal strength of 5/10 and low materiality of 4/10. The highest-conviction signal is the stable multi-year revenue stream through 2027, but the fixed-price structure and small business set-aside introduce execution and margin risk. Key watch items include option exercises and THOR SOLUTIONS' ability to manage fixed-price cost pressures.

1 total filings
· daily

New Federal Contractors — July 18, 2026

This digest covers 7 new federal contracts totaling $1.09 billion, with only 1 defense-related award ($237.8M to KBR for NAVAIR cybersecurity), underscoring a civilian-heavy procurement stream. The dominant theme is stable, multi-year support services across NASA, DOT, DOL, DHS, and Education, with the highest-conviction signal being a $62M student loan servicing contract to Central Research Inc. (potential $150M through 2033) and a $84.9M Job Corps award to Management & Training Corporation, both offering low-risk, long-duration revenue. A key risk is that 5 of 7 contracts are fixed-price, exposing contractors to execution risk, while the absence of defense contracts limits exposure to NDAA-driven growth. Investors should watch option exercises on the Central Research and THOR SOLUTIONS contracts as near-term catalysts for revenue visibility.

7 total filings
· daily

New Drug Approvals (Original) — July 18, 2026

This digest covers 8 FDA approvals from July 13–16, 2026, characterized by a notable absence of NMEs and biosimilars, with all approvals classified as 'Other' (likely generic or label expansion). The period is dominated by 6 neutral-signal generic/biosimilar entries and 2 bullish signals. The highest-conviction event is the NME approval of GEDATOLISIB (REVTORPYK) by CELCUITY INC., granted Priority Review, signaling a potentially high-value oncology or rare disease asset despite undisclosed commercial details. The second bullish signal is a label expansion for ENLICITIDE CHLORIDE from MERCK SHARP AND DOHME LLC, reinforcing Merck's commercial execution. A key risk is the lack of NME or biosimilar designations in the data, which may reflect data classification issues; investors should verify the approval types for GEDATOLISIB and ENLICITIDE. The period shows no dominant therapeutic area theme, with approvals spanning anesthesia (PROPOFOL), oncology (AFATINIB), neurology (BRIVARACETAM), psychiatry (ALPRAZOLAM), and hematology (ELTROMBOPAG).

8 total filings
· daily

Significant Contract Modifications ($10M+) — July 18, 2026

This digest covers 7 significant contract modifications totaling $1.09 billion, with a striking 6-to-1 civilian-to-defense split, underscoring a non-defense-heavy procurement environment. The dominant theme is civilian agency infrastructure and services, led by NASA ($513.7M combined for AERIE AEROSPACE and Astrion Group) and the Department of Education ($62.1M for Central Research Inc.), signaling stable demand for lab support, engineering, and loan servicing. The highest-conviction signal is Central Research Inc.'s $150M potential student loan servicing contract through 2033, offering a long-term, merit-based revenue stream. A key risk is the fixed-price nature of 4 of 7 contracts, which exposes contractors like H-K CONTRACTORS and THOR SOLUTIONS to execution and cost-overrun risk, particularly in construction and engineering services.

7 total filings
· daily

Contract Deobligations Alert — July 18, 2026

This digest of 7 contracts totaling $1.09 billion reveals a heavily civilian-weighted procurement landscape, with only 1 of 7 awards (14%) defense-related, signaling a near-term lull in DOD contract activity. The dominant theme is stable, multi-year service support for civilian agencies, led by NASA ($513.7M combined to AERIE AEROSPACE and Astrion Group) and the Department of Education ($62.1M to Central Research Inc.). The highest-conviction signal is the bullish, long-term student loan servicing contract for Central Research Inc., which has a potential value of $150M through 2033, offering a durable revenue stream. A key risk is the concentration of awards to private companies (5 of 7), limiting public market exposure, and the fixed-price nature of several contracts (H-K CONTRACTORS, THOR SOLUTIONS, Central Research) which introduces execution risk in a rising cost environment.

7 total filings
· daily

Contract Option Exercises — July 18, 2026

This digest covers 7 contract option exercises totaling $1.09 billion, with only 1 defense-related award (KBR WYLE SERVICES, LLC for $237.8M in NAVAIR cybersecurity), underscoring a dominant civilian agency theme led by NASA ($513.7M combined) and infrastructure/education contracts. The highest-conviction signal is the bullish, long-term $62.1M Department of Education student loan servicing award to Central Research Inc. (potential $150M through 2033), indicating stable civilian revenue. Key risks include fixed-price execution risk on 4 of 7 contracts (totaling $418.3M) and the historical nature of the largest award ($351.4M to AERIE AEROSPACE), which provides no current revenue. Investors should watch for option exercises on the THOR SOLUTIONS LLC and Central Research Inc. contracts as catalysts.

7 total filings
· daily

Federal Professional Services Contracts — July 18, 2026

The digest covers a single $73M civilian contract from the Department of Homeland Security (Coast Guard) to THOR SOLUTIONS LLC, a Service-Disabled Veteran-Owned Small Business, for engineering support services. This award signals sustained investment in technical services within DHS, but the fixed-price structure and small business set-aside introduce execution risk and limit scalability. The neutral signal strength reflects steady but not high-growth demand, with the key watch item being the exercise of options to confirm budget continuity and contractor performance.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — July 18, 2026

This digest covers a single $237.8 million time-and-materials delivery order awarded to KBR, Inc. by the General Services Administration (GSA) for NAVAIR cybersecurity services, representing the entirety of the $237.8 million total obligation. The contract is 100% defense-related, supporting the Navy's Naval Air Systems Command, and carries a neutral signal with medium conviction. The highest-conviction signal is KBR's competitive win in a full-and-open competition, indicating technical merit in a stable defense cybersecurity spending environment. A key risk is the contract's advanced stage (awarded in 2019) and time-and-materials pricing, which introduces cost risk and limits upside visibility for investors.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 18, 2026

The digest covers $872.1 million in obligations across four contracts, with only one defense-related award (KBR WYLE SERVICES, LLC for NAVAIR cybersecurity) and three civilian contracts from NASA and DOT. The dominant theme is stable, mission-critical support services for federal agencies, with NASA accounting for $513.7 million (59%) of total obligations. The highest-conviction signal is KBR's $237.8 million cybersecurity delivery order, which underscores growing defense IT security demand, though the contract is in its later stages. A key risk is the historical nature of the AERIE AEROSPACE contract, which ended in 2022 and provides no current revenue visibility.

4 total filings
· daily

High-Value Federal Grants ($5M+) — July 18, 2026

This digest covers seven high-value federal contracts totaling $1.09 billion, with only one defense-related award (KBR WYLE SERVICES, LLC at $237.8M for NAVAIR cybersecurity), underscoring a predominantly civilian procurement theme. The dominant sector is civilian infrastructure and services, led by NASA (two contracts worth $513.7M combined) and the Department of Education ($62.1M for student loan servicing). The highest-conviction signal is the Department of Education’s award to Central Research Inc., which offers a long-term, merit-based revenue stream through 2033. Key risks include the fixed-price nature of several contracts (e.g., H-K CONTRACTORS’ $120.6M bridge project and THOR SOLUTIONS LLC’s $73M Coast Guard award) and the fact that the largest contract (AERIE AEROSPACE’s $351.4M NASA award) is already completed, providing no current revenue. Investors should watch for option exercises on the Central Research Inc. and THOR SOLUTIONS LLC contracts as catalysts for revenue growth, while monitoring potential budget uncertainty from continuing resolutions affecting civilian agency spending.

7 total filings
· daily

General Federal Contracts — July 18, 2026

This digest covers $1.09 billion in federal obligations across 7 contracts, with only 1 defense-related award (KBR WYLE SERVICES, LLC for $237.8M in NAVAIR cybersecurity), underscoring a civilian-heavy procurement stream. NASA dominates with two large awards totaling $513.7M (AERIE AEROSPACE and Astrion Group), signaling sustained investment in space-related engineering and laboratory support. The highest-conviction bullish signals come from Management & Training Corporation ($84.9M DOL Job Corps contract) and Central Research Inc. ($62M Education student loan servicing), both with low-risk pricing structures and multi-year revenue visibility. Key risk: the AERIE AEROSPACE contract is already completed, providing no forward revenue, while the KBR contract is in its later stages with potential re-compete vulnerability.

7 total filings
· daily

All NASA Contracts — July 18, 2026

The two NASA contracts analyzed, totaling $513.7 million in obligations, represent a purely civilian space agency investment with no defense exposure. The dominant theme is NASA's sustained investment in technical and laboratory support services at its Marshall and Kennedy Space Centers, with AERIE AEROSPACE LLC ($351.4M) and Astrion Group, LLC ($162.3M) as the primary recipients. The highest-conviction signal is Astrion's competitive win under full-and-open competition, indicating a stable revenue stream through 2026, though the fixed-price structure carries execution risk. A key risk is that the AERIE contract has already ended, making it a historical data point with no current revenue contribution, while Astrion's heavy reliance on 112 subawards ($49.2M) introduces subcontractor performance risk.

2 total filings